Indevus Pharmaceuticals (NASDAQ:IDEV) Investors: Investor Lawsuit On In Effort to Stop 'Unfair' Sale

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) January 16, 2009 -- A shareholder of Indevus Pharmaceuticals Inc (NASDAQ: IDEV) has filed a lawsuit on behalf of investors in Indevus Pharmaceuticals Inc (NASDAQ: IDEV) in effort to prevent its sale to Endo Pharmaceuticals Inc (ENDP.O) for $370 million. The lawsuit alleges that the company and its directors breached their fiduciary duties by agreeing to the offer and merger at an inadequate price
If you are currently hold shares of Indevus Pharmaceuticals (NASDAQ: IDEV) you have certain options, and you should contact the Shareholders Foundation, Inc immediately!

1

Indevus Pharmaceuticals (NASDAQ:IDEV) Investors: Investor Lawsuit On In Effort to Stop 'Unfair' Sale

Welcome visit Our WebSite:

http://www.shareholdersfoundation.com

Email:mailto: Mail@ShareholdersFoundation.com

or Call us TODAY!

Phone: +1-(858)-779-1554

Last week,Endo Pharmaceuticals announced to acquire Indevus Pharmaceuticals (NASDAQ: IDEV). Indevus Pharmaceuticals, Inc. (Indevus) is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. Under the terms of the proposed agreement, shareholders of Indevus Pharmaceuticals (NASDAQ: IDEV) will receive $4.50 cash for each share of Indevus Pharmaceuticals (NASDAQ: IDEV) they own. Indevus Pharmaceuticals (NASDAQ: IDEV) shareholders may also receive up to and additional $3.00 per share if certain regulatory and sales milestones are met over the next five years. The Board of Directors of Indevus Pharmaceuticals (NASDAQ: IDEV) agreed to a "no-solicitation" provision and a $20 million termination fee which will ensure no superior offer will ever be forthcoming. According to the lawsuit the shareholder claims arise from potential breaches of fiduciary duty and other violations of state law by the board of directors of Indevus Pharmaceuticals arising out of their attempt to sell the company to Endo Pharmaceuticals. Indevus Pharmaceuticals (NASDAQ: IDEV) shares traded above $6.50 during 2008 and in 2007 for over $7.8.

If you are currently hold shares of Indevus Pharmaceuticals (NASDAQ: IDEV) you have certain options, and you should contact the Shareholders Foundation, Inc immediately!

Email: Mail@ShareholdersFoundation.com

or Call us TODAY!

Phone: +1-(858)-779-1554

or send us your information by mail /facsimile:


Shareholders Foundation, Inc.
Allen Trevor
3111 Camino Del Rio North - Suite 423 -
92108 San Diego
Tel:+1-(858)-779-1554
Fax:+1-(858)-605-5739

Mail@ShareholdersFoundation.com
www.ShareholdersFoundation.com
____________________________________________________________________________

Advertising. At Shareholders Foundation, Inc. we are in contact with a large number of shareholders. We are able to use our size to negotiate with significantly greater efficacy than the single investor with investigators, attorneys, and defendants. At Shareholders Foundation, Inc. we believe that together we can combine the interests of many investors, and use the size of our interest as leverage against the giant corporations. We offer help, support, and assistance for every shareholder by matching shareholder problems with the right legal experts, and finding equitable solutions. Shareholders Foundation, Inc. is comprised of a network of legal experts who both contribute to our vision for the Shareholders Foundation, Inc. and also represent the shareholders in real cases. The Shareholders Foundation, Inc. is not a law firm. Any statements made in press releases, emails or over the phone by any member or personnel employed by Shareholders Foundation, Inc. or by third parties related to the Shareholders Foundation, Inc. is provided for research and guidance purposes only and are not legal advices, as we can not give you legal advice. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

More information can be found online at http://www.shareholdersfoundation.com

     acquisition     buyout     IDEV     Indevus     Indevus Pharmaceuticals     lawsuit     merger     nasdaq